Clinical trial
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis…
NCT02334748 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT02334748 |
|---|---|
| Title | A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies |
| Official title | A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers |
| Intervention type | Drug |
| Interventions | canakinumab |
| Enrollment | 31 |
| Start date | Nov 3, 2014 |
| Primary completion | Aug 31, 2018 |
| Completion | Aug 31, 2018 |
| First posted | Jan 8, 2015 |
| Last update posted | May 19, 2020 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: